Millennium and COR Therapeutics Agree to Merge, Creating Integrated Biopharmaceutical Company

07-Dec-2001

Millennium Pharmaceuticals, Inc. and COR Therapeutics, Inc. today announced that they have signed a definitive agreement for Millennium to acquire COR in a stock-for-stock exchange valued at $2.0 billion. The combined company will be named Millennium Pharmaceuticals, Inc., with worldwide headquarters in Cambridge, Massachusetts. This merger will create a leading biopharmaceutical company with multiple products on the market, nine candidate products in human clinical trials, four therapeutic franchise areas, a strong commercial operating presence, and more than 1,200 employees in research and development. The two companies bring together complementary capabilities by uniting COR’s cardiovascular expertise, product pipeline, and commercial infrastructure for its market-leading anti-platelet cardiovascular product, INTEGRILIN® (eptifibatide) Injection, with Millennium’s genomic-based research, drug discovery and development technology platform, business leadership in strategic alliances, and product pipeline in oncology, inflammation and metabolic disease. This merger serves as a key milestone in achieving Millennium’s goal of creating a major biopharmaceutical company.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Novel HCMV compound of AiCuris in phase IIb trial with bone marrow transplant recipients

DURAN Group launches anniversary campaign to celebrate 120 years of laboratory glassware

DURAN Group launches anniversary campaign to celebrate 120 years of laboratory glassware

MedMira Extends Market Reach into Southeast Asia with Contract for One Million HIV Tests - SE Asia Latest Target Market in Growing Global Distributor Network

SAFC and Novozymes Biopharma extend joint agreement for the exclusive distribution of LONGR3 growth factor

ARIUS Research Signs Anti-Cancer Antibody Discovery Deal with Takeda - Three-Year Collaboration to look for Novel Cancer Treatments

Amorfix announces Michael Sonnenreich as new director and establishment of a scientific advisory board

ALTANA AG: Sale of pharmaceuticals business to Nycomed - Purchase price of approx. EUR4.5 billion

MediGene and The Johns Hopkins University Sign Development Collaboration for First Vaccine Candidates from MediGene's AAVLP Platform - Examination of product candidates for the prevention of HPV-associated diseases

Lexicon Genetics Initiates Clinical Trials of LX1031 for Irritable Bowel Syndrome

AMRI promotes Richard A. Saffee to Vice President and General Manager of Large Scale Manufacturing

Market Opportunities Abound for Life Science Suppliers in Multi-Billion Dollar U.S. Market for Biodefense Research

MIT biologists find that restoring the gene for cancer protein p53 slows spread of advanced tumors